Tech

Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments (Lizette Chapman/Bloomberg)



Lizette Chapman / Bloomberg:

Palantir wins a three-year deal worth $44.4M with the FDA to use Palantir software to power drug reviews and inspections, including possible COVID-19 treatments  —  Palantir Technologies Inc. won a deal with the U.S. Food and Drug Administration to help power drug reviews and inspections …




Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button